Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3995
Single User License Price INR 284684
Corporate User License Price USD 11985
Corporate User License Price INR 854051
Site License Price USD 7990
Site License Price INR 569367
Request a Quote

Report Title

Pain Drug Development Pipeline Review, 2018

Quote Request for License Type
License Type Price  
Single User License USD 3995
Site License USD 7990
Enterprise Wide License USD 11985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Pain Drug Development Pipeline Review, 2018


Quote Request for License Type
License Type Price  
Single User License USD 3995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Pain Drug Development Pipeline Review, 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Pain Drug Development Pipeline Review, 2018



Executive Summary

Pain Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for pain disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-operative pain, fibromyalgia, complex regional pain syndrome (CRPS) and visceral pain, and features dormant and discontinued products.

Pain is one of the main post-operative adverse outcomes causing distress to patients. Causes of post-operative pain include peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics. There are 74 products in development for this indication.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs. There are 21 products in development for this indication.

CRPS is a chronic pain condition that most often affects one limb, usually after an injury. CRPS is divided into two types: CRPS-I (individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in the affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams. There are seven products in development for this indication.

Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or nonsteroidal anti-inflammatory drugs and pain modifiers such as tricyclic antidepressants or anticonvulsants. There are 38 products in development for this indication.

Molecular targets acted on by products in development for pain disorders include beta nerve growth factor, cannabinoid receptors, opioid receptors and protein kinases. Companies operating in this pipeline space include NeurAxon, Abide Therapeutics and Pfizer.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 9

2.1 Pain Report Coverage 9

2.2 Post-Operative Pain - Overview 9

2.3 Fibromyalgia - Overview 9

2.4 Complex Regional Pain Syndrome - Overview 9

2.5 Visceral Pain - Overview 9

3 Therapeutics Development 10

3.1 Post-Operative Pain 10

3.2 Fibromyalgia 18

3.3 Complex Regional Pain Syndrome 22

3.4 Visceral Pain 25

4 Therapeutics Assessment 32

4.1 Post-Operative Pain 32

4.2 Fibromyalgia 42

4.3 Complex Regional Pain Syndrome 49

4.4 Visceral Pain 54

5 Companies Involved in Therapeutics Development 62

5.1 Post-Operative Pain 62

5.2 Fibromyalgia 85

5.3 Complex Regional Pain Syndrome 91

5.4 Visceral Pain 93

6 Dormant Projects 103

6.1 Post-Operative Pain 103

6.2 Fibromyalgia 106

6.3 Complex Regional Pain Syndrome 107

6.4 Visceral Pain 108

7 Discontinued Products 111

7.1 Post-Operative Pain 111

7.2 Fibromyalgia 112

7.3 Visceral Pain 112

8 Product Development Milestones 114

8.1 Post-Operative Pain 114

8.2 Fibromyalgia 127

8.3 Complex Regional Pain Syndrome 138

8.4 Visceral Pain 141

9 Appendix 147

9.1 Methodology 147

9.2 Coverage 147

9.3 Secondary Research 147

9.4 Primary Research 147

9.5 Expert Panel Validation 147

9.6 Contact Us 148

9.7 Disclaimer 148

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Number of Products under Development for Post-Operative Pain 10

Figure 2: Number of Products under Development by Companies, Post-Operative Pain 11

Figure 3: Number of Products under Development by Universities/Institutes, Post-Operative Pain 14

Figure 4: Number of Products under Development for Fibromyalgia 18

Figure 5: Number of Products under Development by Companies, Fibromyalgia 19

Figure 6: Number of Products under Development for Complex Regional Pain Syndrome 22

Figure 7: Number of Products under Development by Companies, Complex Regional Pain Syndrome 23

Figure 8: Number of Products under Development for Visceral Pain 25

Figure 9: Number of Products under Development by Companies, Visceral Pain 26

Figure 10: Number of Products under Development by Universities/Institutes, Visceral Pain 28

Figure 11: Number of Products by Top 10 Targets, Post-Operative Pain 32

Figure 12: Number of Products by Stage and Top 10 Targets, Post-Operative Pain 32

Figure 13: Number of Products by Top 10 Mechanism of Actions, Post-Operative Pain 35

Figure 14: Number of Products by Stage and Top 10 Mechanism of Actions, Post-Operative Pain 35

Figure 15: Number of Products by Top 10 Routes of Administration, Post-Operative Pain 38

Figure 16: Number of Products by Stage and Top 10 Routes of Administration, Post-Operative Pain 38

Figure 17: Number of Products by Molecule Types, Post-Operative Pain 40

Figure 18: Number of Products by Stage and Molecule Types, Post-Operative Pain 40

Figure 19: Number of Products by Top 10 Targets, Fibromyalgia 42

Figure 20: Number of Products by Stage and Top 10 Targets, Fibromyalgia 42

Figure 21: Number of Products by Top 10 Mechanism of Actions, Fibromyalgia 44

Figure 22: Number of Products by Stage and Top 10 Mechanism of Actions, Fibromyalgia 44

Figure 23: Number of Products by Routes of Administration, Fibromyalgia 46

Figure 24: Number of Products by Stage and Routes of Administration, Fibromyalgia 46

Figure 25: Number of Products by Molecule Types, Fibromyalgia 47

Figure 26: Number of Products by Stage and Molecule Types, Fibromyalgia 48

Figure 27: Number of Products by Targets, Complex Regional Pain Syndrome 49

Figure 28: Number of Products by Stage and Targets, Complex Regional Pain Syndrome 49

Figure 29: Number of Products by Mechanism of Actions, Complex Regional Pain Syndrome 50

Figure 30: Number of Products by Stage and Mechanism of Actions, Complex Regional Pain Syndrome 51

Figure 31: Number of Products by Routes of Administration, Complex Regional Pain Syndrome 52

Figure 32: Number of Products by Stage and Top 10 Routes of Administration, Complex Regional Pain Syndrome 52

Figure 33: Number of Products by Stage and Molecule Types, Complex Regional Pain Syndrome 53

Figure 34: Number of Products by Top 10 Targets, Visceral Pain 54

Figure 35: Number of Products by Stage and Top 10 Targets, Visceral Pain 54

Figure 36: Number of Products by Top 10 Mechanism of Actions, Visceral Pain 56

Figure 37: Number of Products by Stage and Top 10 Mechanism of Actions, Visceral Pain 56

Figure 38: Number of Products by Routes of Administration, Visceral Pain 58

Figure 39: Number of Products by Stage and Routes of Administration, Visceral Pain 59

Figure 40: Number of Products by Molecule Types, Visceral Pain 60

Figure 41: Number of Products by Stage and Molecule Types, Visceral Pain 60

1.1 List of Tables

Table 1: Number of Products under Development for Post-Operative Pain 10

Table 2: Number of Products under Development by Companies, Post-Operative Pain 12

Table 3: Number of Products under Development by Universities/Institutes, Post-Operative Pain 14

Table 4: Products under Development by Companies, Post-Operative Pain 15

Table 5: Products under Development by Universities/Institutes, Post-Operative Pain 18

Table 6: Number of Products under Development for Fibromyalgia 19

Table 7: Number of Products under Development by Companies, Fibromyalgia 20

Table 8: Number of Products under Development by Universities/Institutes, Fibromyalgia 20

Table 9: Products under Development by Companies, Fibromyalgia 21

Table 10: Products under Development by Universities/Institutes, Fibromyalgia 22

Table 11: Number of Products under Development for Complex Regional Pain Syndrome 22

Table 12: Number of Products under Development by Companies, Complex Regional Pain Syndrome 23

Table 13: Number of Products under Development by Universities/Institutes, Complex Regional Pain Syndrome 24

Table 14: Products under Development by Companies, Complex Regional Pain Syndrome 24

Table 15: Products under Development by Universities/Institutes, Complex Regional Pain Syndrome 24

Table 16: Number of Products under Development for Visceral Pain 25

Table 17: Number of Products under Development by Companies, Visceral Pain 27

Table 18: Number of Products under Development by Universities/Institutes, Visceral Pain 28

Table 19: Products under Development by Companies, Visceral Pain 29

Table 20: Products under Development by Universities/Institutes, Visceral Pain 31

Table 21: Number of Products by Stage and Target, Post-Operative Pain 33

Table 22: Number of Products by Stage and Mechanism of Action, Post-Operative Pain 36

Table 23: Number of Products by Stage and Route of Administration, Post-Operative Pain 39

Table 24: Number of Products by Stage and Molecule Type, Post-Operative Pain 41

Table 25: Number of Products by Stage and Target, Fibromyalgia 43

Table 26: Number of Products by Stage and Mechanism of Action, Fibromyalgia 45

Table 27: Number of Products by Stage and Route of Administration, Fibromyalgia 47

Table 28: Number of Products by Stage and Molecule Type, Fibromyalgia 48

Table 29: Number of Products by Stage and Target, Complex Regional Pain Syndrome 50

Table 30: Number of Products by Stage and Mechanism of Action, Complex Regional Pain Syndrome 51

Table 31: Number of Products by Stage and Route of Administration, Complex Regional Pain Syndrome 53

Table 32: Number of Products by Stage and Molecule Type, Complex Regional Pain Syndrome 53

Table 33: Number of Products by Stage and Target, Visceral Pain 55

Table 34: Number of Products by Stage and Mechanism of Action, Visceral Pain 57

Table 35: Number of Products by Stage and Route of Administration, Visceral Pain 59

Table 36: Number of Products by Stage and Molecule Type, Visceral Pain 61

Table 37: Post-Operative Pain - Pipeline by Abide Therapeutics Inc 62

Table 38: Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc 62

Table 39: Post-Operative Pain - Pipeline by Adynxx Inc 63

Table 40: Post-Operative Pain - Pipeline by AngioChem Inc 63

Table 41: Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc 64

Table 42: Post-Operative Pain - Pipeline by Apsen Farmaceutica SA 64

Table 43: Post-Operative Pain - Pipeline by Cadila Healthcare Ltd 65

Table 44: Post-Operative Pain - Pipeline by Camurus AB 65

Table 45: Post-Operative Pain - Pipeline by Cara Therapeutics Inc 66

Table 46: Post-Operative Pain - Pipeline by Center Laboratories Inc 66

Table 47: Post-Operative Pain - Pipeline by CerSci Therapeutics Inc 67

Table 48: Post-Operative Pain - Pipeline by Colby Pharmaceutical Co 67

Table 49: Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA 68

Table 50: Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc 68

Table 51: Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc 69

Table 52: Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp 69

Table 53: Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc 70

Table 54: Post-Operative Pain - Pipeline by Heron Therapeutics Inc 70

Table 55: Post-Operative Pain - Pipeline by Immupharma Plc 71

Table 56: Post-Operative Pain - Pipeline by Innocoll AG 71

Table 57: Post-Operative Pain - Pipeline by Insys Therapeutics Inc 72

Table 58: Post-Operative Pain - Pipeline by Ionis Pharmaceuticals Inc 72

Table 59: Post-Operative Pain - Pipeline by iX Biopharma Ltd 73

Table 60: Post-Operative Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd 73

Table 61: Post-Operative Pain - Pipeline by Lipocure Ltd 74

Table 62: Post-Operative Pain - Pipeline by Liquidia Technologies Inc 74

Table 63: Post-Operative Pain - Pipeline by Lumosa Therapeutics Co Ltd 74

Table 64: Post-Operative Pain - Pipeline by Medtronic Plc 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Abide Therapeutics Inc

Abiogen Pharma SpA

AcelRx Pharmaceuticals Inc

Addex Therapeutics Ltd

Adynxx Inc

Anavex Life Sciences Corp

AngioChem Inc

Aoxing Pharmaceutical Company Inc

Apsen Farmaceutica SA

Aptinyx Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Astellas Pharma Inc

Cadila Healthcare Ltd

Camurus AB

Cara Therapeutics Inc

Center Laboratories Inc

CerSci Therapeutics Inc

Chromocell Corp

Colby Pharmaceutical Co

Daiichi Sankyo Co Ltd

Dompe Farmaceutici SpA

Echo Pharmaceuticals BV

Eisai Co Ltd

Eli Lilly and Co

Eupraxia Pharmaceuticals Inc

EyeGate Pharmaceuticals Inc

Fujimoto Pharmaceutical Corp

Grunenthal GmbH

GW Pharmaceuticals Plc

Heron Therapeutics Inc

Idera Pharmaceuticals Inc

Immupharma Plc

Innocoll AG

Innovative Med Concepts LLC

Insys Therapeutics Inc

Intec Pharma Ltd

Ionis Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

iX Biopharma Ltd

Jiangsu Hengrui Medicine Co Ltd

Kyorin Pharmaceutical Co Ltd

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

Lipocure Ltd

Liquidia Technologies Inc

Lumosa Therapeutics Co Ltd

Luye Pharma Group Ltd

Medtronic Plc

Merck & Co Inc

Mundipharma International Ltd

Neumentum Inc

Novartis AG

Ocular Therapeutix Inc

Pacira Pharmaceuticals Inc

PainReform Ltd

Pfizer Inc

Pharmaleads SA

PhytoHealth Corp

Piramal Enterprises Ltd

PixarBio Corp

PolyPid Ltd

Prismic Pharmaceuticals Inc

RaQualia Pharma Inc

Recro Pharma Inc

Serina Therapeutics Inc

SteadyMed Therapeutics Inc

Taiwan Liposome Company Ltd

Teikoku Pharma USA Inc

Tetra Bio-Pharma Inc

Trevena Inc

UCB SA

Urigen Pharmaceuticals Inc

Virpax Pharmaceuticals Inc

Vitality Biopharma Inc

Xigen SA

YiChang Humanwell Pharmaceutical Co Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person